Article Versions Notes

Goksøyr L, Skrzypczak M, Sampson M, Nielsen MA, Salanti A, Theander TG, Remaley AT, De Jongh WA, Sander AF. A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines. Vaccines. 2023; 11(1):2. https://doi.org/10.3390/vaccines11010002

Goksøyr, Louise, Magdalena Skrzypczak, Maureen Sampson, Morten A. Nielsen, Ali Salanti, Thor G. Theander, Alan T. Remaley, Willem A. De Jongh, and Adam F. Sander. 2023. "A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines" Vaccines 11, no. 1: 2. https://doi.org/10.3390/vaccines11010002

Goksøyr, L., Skrzypczak, M., Sampson, M., Nielsen, M. A., Salanti, A., Theander, T. G., Remaley, A. T., De Jongh, W. A., & Sander, A. F. (2023). A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines. Vaccines, 11(1), 2. https://doi.org/10.3390/vaccines11010002